Stock 4523 EISAI CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Eisai Co., Ltd.

Equities

4523

JP3160400002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-23 am EDT 		5-day change 1st Jan Change
6,090 JPY -0.03% Intraday chart for Eisai Co., Ltd. +0.63% -13.64%
12:00pm Alzheimer's drug adoption in US slowed by doctors' skepticism RE
Apr. 01 Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.79 times its estimated earnings per share for the ongoing year.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
EISAI CO., LTD. Stock Eisai Co., Ltd.
-13.64% 11.29B
A-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.46% 659B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.66% 557B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.86% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.44% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.34% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.15% 215B
B+
NOVARTIS AG Stock Novartis AG
+7.18% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
A+
PFIZER, INC. Stock Pfizer, Inc.
-8.79% 149B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4523 Stock
  4. Ratings Eisai Co., Ltd.